Zoetis PFL5330 Solidbac® Pinkeye IR / PR Pellet, 50 Dose, For Cattle
Product Code: PFL5330
Solidbac® Pinkeye IR/PR Pellet, 50 Dose, 2 - 7 Deg C Storage Temperature, Gentamicin, Moraxella Bovis Bacterin, Cattle Species
- Dosage : 50 Dose
- Ingredients : Gentamicin, Moraxella Bovis Bacterin
- Species : Cattle
- Storage Temperature : 2 - 7 Deg C
Moraxella Bovis Bacterin For the vaccination of healthy cattle as an aid in the prevention and control of pinkeye (infectious bovine keratoconjunctivitis) caused by Moraxella bovis. SolidBac® Pinkeye IR/PR makes vaccination against pinkeye caused by Moraxella bovis an easy, one-step process. SolidBac Pinkeye IR/PR combines two, tiny antigen pellets -- an Immediate Release (IR) pellet and a Programmed Release (PR) pellet – and delivers them simultaneously using the SoliDoser® applicator. Each channel of a 10-dose plastic clip contains a color-coded, dual-dose pelleted product. Using the SoliDoser® device, two tiny pellets are administered subcutaneously in the base of the ear or in the neck. Precautions: Store at 2° - 7° C (35° - 45° F). Disinfect and dry needle between doses. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Preservative: Gentamicin. Administer epinephrine if allergic reaction occurs.
• Uses: SolidBac Pinkeye IR/PR is for the vaccination of healthy cattle as an aid in prevention and control of pinkeye (infectious bovine keratoconjunctivitis) caused by Moraxella bovis • Season-Long Protection: For the best protection, vaccinate in the spring prior to the beginning of the fly season. The patented technology helps provide protection with the Immediate Release (IR) antigen pellet which is boostered automatically by the Programmed Release (PR) antigen pellet. The result is solid, season-long pinkeye protection with just one administration • Broad Spectrum Protection: Contains 8 different isolates of the pinkeye causing Moraxella bovis bacteria • Demonstrated in a recent challenge study to help prevent pinkeye in more than 90% of vaccinates • Demonstrated in a recent challenge study to aid in reducing pinkeye damage by more than 96%, 6 days post-challenge
• Low endotoxin: Proprietary endotoxin reducing technology results in a pinkeye bacterin with low free-endotoxin levels. • Tissue friendly: Low subcutaneous dose in the base of the ear or in the neck. • Small needle diameter means less injection site trauma. • No warnings about injection site reactions on the label, unlike some other popular pinkeye vaccines.